Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON42959
NL-OMON42959
Withdrawn
Not Applicable

Intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers - MABs therapy m.3243A>G mutation carriers

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites5 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsmitochondrial myopathymitochondrial muscular disease10028302

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
mitochondrial myopathy
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
5
Status
Withdrawn
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Adult carriers of a m.3243A\>G mutation in muscle \>30%

Exclusion Criteria

  • •Significant concurrent illness
  • •Pregnant or lactating women
  • •Psychiatric or other disorders likely to impact on informed consent
  • •Patients unable and/or unwilling to comply with treatment and study instructions
  • •Any other factor that in the opinion of the investigator excludes the patient from the study
  • •Allergy contrast fluid

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Allogenic mesenchymal stem cell intraarticular injection for knee osteoarthritis therapy, an RCT explorative mode-of-action study
CTIS2023-506088-33-00Aarhus University80
Recruiting
Phase 1
Allogenic mesenchymal stem cell intraarticular injection for knee osteoarthritis therapy, an RCT explorative mode-of-action studyknee osteoarthritisMedDRA version: 21.1Level: LLTClassification code: 10023476Term: Knee osteoarthritis Class: 10028395Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
CTIS2023-506088-33-01Aarhus University80
Recruiting
Not Applicable
Intra Coronary Autologous Stem Cell Transplantation in Acute Myocardial Infarction (AMI
CTRI/2010/091/000643Global Medical education & Research Center50
Completed
Not Applicable
Assess safety of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriersmitochondrial myopathymitochondrial muscular disease10028302
NL-OMON50120Medisch Universitair Ziekenhuis Maastricht15
Recruiting
Phase 2
Intravenous infusion of autologous mesenchymal stem cells from bone marrow for chronic brain injury patients (PhaseII)Chronic brain injury
JPRN-jRCT1090220333Osamu Honmou, MD, PhD10